Argent Biopharma Limited has released a press release.
Mxc well positioned for tga down-schedule of cbd products
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- $15M finance facility to fund revenue growth for key markets
- Appendix 4E and Preliminary Unaudited Financial Report
- JV to be established for registration of ArtemiC in Russia
- COVID-19 Interim Trial Results Meet All Primary Objectives
- UK distribution agreement signed for MGC Pharma medicines
Later from Argent Biopharma
- Mxc welcomes new fca guidance for cannabis sector in the uk
- Update on ArtemiC phase II trial on COVID-19 patients
- Mgc pharma launches cannepil app
- First high thc products shipped direct to Brazil patients
- Artemic histology on rats confirm no pathological impact
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma